imatinib mesylate has been researched along with Biliary Tract Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
| Caca, K; Deininger, M; Feisthammel, J; Kreth, F; Mössner, J; Wiedmann, M | 1 |
2 other study(ies) available for imatinib mesylate and Biliary Tract Cancer
| Article | Year |
|---|---|
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |
Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Fluorouracil; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2003 |